Pharmacokinetics Of Celecoxib Test Formulations

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.

Key facts

Study ID

NCT00925106

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

16

Starts

2009-07-01

Expected to finish

2009-08-01

Last updated by the study team

2021-02-02

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female volunteers
• Body weight BMI 17.5-30.5

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
• Positive urine drug screen

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.